X4 Pharmaceuticals, Inc (XFOR): restructuring charge — X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart

X4 Pharmaceuticals, Inc

Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.
Cash charges of ~$3.3M for severance and termination-related costs; substantially complete in Q3 2025.
COO Mary DiBiase, CCO Mark Baldry, CLO Natasha Thoren terminated; CMO Christophe Arbet-Engels resigns.
John Volpone appointed COO in addition to his role as President; Executive Chairman Adam Craig oversees clinical development.
Restructuring aims to focus resources on completing the 4WARD Phase 3 trial for chronic neutropenia.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.3 million for severance and other employee termination-related costs affecting the Company (reduce its workforce by approximately 50%).

Type: restructuring
Charge: approximately $3.3 million for severance and other employee termination-related costs
Affected area: the Company
Headcount: reduce its workforce by approximately 50%

Exact text from the filing

On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‐term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.

View on SEC.gov

7 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001501697-25-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.